Drug application
NALTREXONE (NALTREXONE)
Drugs@FDA ANDA 213195 · TEVA PHARMS USA INC
Key facts
| Drug name | NALTREXONE |
|---|---|
| Active ingredients | NALTREXONE |
| Application type | ANDA |
| Application number | 213195 |
| Company | TEVA PHARMS USA INC |
| Dosage forms | FOR SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR |
| Strength | 380MG/VIAL |
| Marketing status | Discontinued |
| TE codes | AP |
| Reference listed drug | No |
| Latest submission status date | Jul 6, 2023 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
- Yes FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: